traffick
inflamm
airway
diseas
part
modul
member
cc
chemokin
famili
transduc
signal
receptor
context
hypothes
transfect
alveolar
type
ii
epitheli
cell
sirna
antisens
asodn
sequenc
downregul
cellular
synthesi
releas
primari
ligand
modul
ligand
human
alveolar
type
ii
epitheliumlik
cell
cultur
model
use
transfect
subsequ
effect
agonist
sirna
particularli
effect
pcr
show
decreas
mrna
immunoblot
show
reduct
sirna
treat
cell
treatment
reduc
stimul
releas
constitut
releas
respect
releas
four
addit
agonist
rant
also
significantli
reduc
treatment
alveolar
type
ii
cell
activ
eosinophil
assess
superoxid
anion
gener
reduc
eosinophil
treat
supernat
cell
pretreat
sirna
asodn
collect
data
suggest
posttranscript
regul
receptor
may
potenti
therapeut
approach
interrupt
proinflammatori
signal
global
initi
asthma
gina
scholar
oper
defin
asthma
chronic
inflammatori
disord
airway
cell
cellular
element
play
role
chronic
inflamm
caus
associ
increas
airway
hyperrespons
lead
episod
wheez
breathless
cough
episod
symptom
may
often
success
treat
chronic
airway
inflamm
insidi
bronchial
biopsi
studi
reveal
asthmat
clinic
remiss
show
ongo
airway
inflamm
remodel
pulmonari
epithelium
emerg
paradigm
asthma
depict
incomplet
repair
damag
epithelium
display
alter
permeabl
releas
increas
amount
numer
growth
factor
cytokin
chemokin
chemokin
orchestr
leukocyt
traffick
state
homeostasi
immun
respons
inflamm
implic
pathogenesi
chronic
diseas
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
emphysema
chronic
bronchiti
chemokin
directli
modul
cell
bioactiv
complex
network
wherein
particular
chemokin
may
bind
multipl
chemokin
receptor
vari
affin
subsequ
direct
migrationactiv
specif
type
inflammatori
leukocyt
exampl
asthma
character
cytokinedriven
elev
cc
chemokin
includ
three
eotaxin
eotaxin
serv
recruit
signal
eosinophil
eo
concomit
increas
lymphocyt
mast
cell
basophil
bidirect
interact
emigr
leukocyt
resid
cell
particular
epithelium
engag
selfsustain
proinflammatori
cycl
three
eotaxin
well
exert
effector
action
bind
high
affin
gproteincoupl
receptor
design
express
eo
basophil
mast
cell
subset
lymphocyt
dendrit
cell
particular
interest
present
studi
find
constitut
express
airway
epitheli
cell
increas
follow
stimul
stimul
also
increas
synthesi
releas
larg
amount
receptoragonist
autocrin
regulatori
mechan
result
downregul
thu
eotaxin
may
contribut
pathogenesi
site
phenotyp
inflamm
leukocyt
recruit
receptor
autoregulatori
mechan
context
antagon
emerg
therapeut
target
treatment
airway
diseas
associ
underli
inflamm
report
approach
inhibit
transduct
signal
focus
synthesi
low
molecular
weight
antagonist
eotaxinneutr
antibodi
attract
altern
includ
antisens
oligonucleotid
asodn
shortinterf
rna
sirna
direct
posttranscript
inhibit
gene
express
rather
block
gene
product
import
recent
report
indic
asodninduc
topic
inhibit
express
may
repres
novel
efficaci
approach
treatment
airway
diseas
therapeut
potenti
sirna
treatment
human
diseas
explor
level
target
identif
product
specif
potenc
deliveri
clinic
effect
studi
involv
sirnabas
treatment
respiratori
diseas
focus
predominantli
viral
infect
acut
lung
injuri
report
involv
eotaxin
limit
delin
factor
modul
synthesi
date
effect
sirna
deliv
human
airway
epitheli
cell
report
thu
experi
design
delin
effect
sirna
asodn
posttranscript
inhibit
gene
express
rest
cell
studi
carri
test
hypothesi
transfect
alveolar
type
ii
cell
asodn
sirna
downregul
alveolar
type
ii
epitheli
cell
synthesi
releas
agonist
also
modul
chemokin
bind
briefli
data
confirm
asodn
sirna
significantli
inhibit
express
concomitantli
decreas
synthesi
releas
well
releas
ligand
supernat
asodn
sirna
treat
cell
significantli
reduc
eosinophil
superoxid
anion
releas
suggest
inhibit
express
alveolar
epithelium
level
may
key
approach
limit
eosinophil
activ
within
airway
human
alveolar
type
ii
epitheliallik
cell
atcc
purchas
american
type
cultur
collect
grown
volvol
supplement
fetal
calf
serum
penicillin
uml
streptomycin
humidifi
atmospher
carbon
dioxid
trypsinedtaor
pbsedtadispers
cell
suspend
fresh
medium
flask
well
cell
ml
experi
perform
subcultur
cell
reach
approxim
confluenc
trypsindispers
cell
wash
resuspend
antibiot
free
medium
supplement
fetal
calf
serum
seed
cellsml
cluster
plate
mlwell
cell
incub
allow
attach
overnight
dharmacon
lafayett
co
transfect
reagent
dharmafect
ontargetplu
smartpool
design
sirna
product
human
consist
duplex
alon
combin
smartpool
use
silenc
dharmacon
sicontrol
nontarget
sirna
pool
use
control
dharmafect
sirna
product
prepar
accord
manufactur
instruct
preliminari
studi
determin
maxim
sirna
effect
protein
seen
hour
post
transfect
nm
sirna
transfect
effici
qualit
assess
treatment
cell
nm
sicontrol
tox
led
cell
death
within
hr
transfect
follow
transfect
monolay
wash
treat
without
ngml
serum
free
medium
hour
cell
cultur
medium
collect
cell
detach
pbsedta
pellet
cell
lysat
prepar
prior
chemokin
andor
cytokin
stimul
cell
subcultur
cluster
plate
cellsml
wash
incub
serumfre
rpmi
vv
medium
contain
indic
concentr
human
predesign
biognostik
germani
antisens
sequenc
id
antisens
sequenc
id
concentr
fugen
transfect
reagent
biognostik
sens
control
revers
complement
target
sequenc
known
human
cross
homolog
includ
experi
cell
incub
hour
addit
ml
complet
medium
ad
cell
cultur
addit
hour
follow
ngml
atlanta
biolog
atlanta
ga
hour
indic
cell
cultur
medium
collect
centrifug
g
minut
supernat
store
analys
carri
treat
cell
detach
mm
edta
pb
centrifug
g
min
wash
twice
cold
facsflow
buffer
bd
bioscienc
san
jose
ca
resuspend
final
concentr
cellsml
aliquot
cell
stain
ngml
biotinyl
human
recombin
eotaxin
neg
control
biotinyl
soybean
trypsin
inhibitor
min
follow
fluorescein
conjug
avidin
flow
cytometri
reagent
r
system
minut
dark
two
wash
cold
facsflow
buffer
stain
cell
maintain
subject
flow
cytometri
facscalibur
data
analyz
use
cellquest
softwar
bd
bioscienc
san
jose
ca
assess
effect
asodn
treatment
receptor
express
airway
epitheli
cell
cellswel
cluster
plate
treat
stimul
detach
describ
cell
suspens
centrifug
g
cell
pellet
resuspend
lysi
buffer
mm
tri
ph
mm
edta
mm
nacl
triton
one
ml
proteas
inhibitor
cocktail
sampl
incub
ice
min
sonic
second
centrifug
min
g
supernat
collect
total
protein
content
lysat
protein
concentr
quantifi
power
wave
x
micropl
reader
equip
powerreport
softwar
biotek
instrument
winooski
vt
usa
cell
lysat
separ
electrophoresi
sdspolyacrylamid
gel
proteinlan
transfer
immobilonp
pvdf
membran
equal
load
verifi
stain
ponceau
sigmaaldrich
chemic
co
st
loui
mo
blot
block
overnight
carnat
instant
milk
pb
contain
tween
pbst
incub
overnight
rabbit
antihuman
affin
purifi
antibodi
imgenex
san
diego
ca
membran
wash
three
time
pbst
incub
goat
antirabbit
igghorseradish
peroxidas
santa
cruz
biotechnolog
ca
pbst
three
hour
wash
three
time
pbst
immunoblot
imag
obtain
use
flour
max
multimag
biorad
laboratori
hercul
ca
protein
load
monitor
probe
membran
antigapdh
antibodi
r
system
minneapoli
mn
lane
densiti
data
acquir
quantiti
one
analysi
softwar
version
biorad
laboratori
hercul
ca
cell
treat
describ
detect
use
minifold
schleiher
schuell
germani
filtrationincub
unit
fit
pb
presoak
nitrocellulos
membran
blot
paper
support
sheet
ten
lysat
protein
water
introduc
manifold
well
vacuum
nitrocellulos
membran
block
pb
contain
bsa
pbst
overnight
wash
three
time
pbst
incub
hr
rabbit
antihuman
antibodi
imgenex
san
diego
ca
follow
three
wash
pbst
membran
incub
goat
antiigghorseradish
peroxidas
santa
cruz
biotechnolog
ca
pbst
contain
bsa
membran
wash
four
time
pbst
incub
five
minut
supersign
pierc
western
substrat
work
solut
imag
obtain
dot
blot
densiti
assess
describ
synthes
secret
protein
detect
use
specif
eotaxin
elisa
kit
r
system
minneapoli
mn
elisa
recogn
natur
recombin
human
eotaxin
quantifi
power
wave
x
micropl
reader
equip
powerreport
softwar
airway
epitheli
cell
plate
cellsml
well
plate
allow
attach
night
cell
transfect
hr
describ
treat
cell
monolay
wash
incub
serumfre
medium
hr
follow
treatment
without
ngml
fresh
serum
free
medium
hr
total
rna
isol
use
dna
free
total
rna
extract
kit
follow
protocol
manufactur
intron
biotechnolog
distribut
boca
scientif
inc
boca
raton
fl
firststrand
cdna
synthes
total
rna
reaction
volum
use
iscript
cdna
synthesi
kit
recommend
manufactur
biorad
laboratori
cdna
synthesi
thermalcycl
program
includ
three
step
min
min
min
pcr
amplif
perform
accord
primer
manufactur
protocol
r
system
gapdh
r
system
serv
intern
control
sampl
cdna
amplifi
pcr
reaction
mixtur
itaq
buffer
mm
mncl
mm
dntp
itaq
dna
polymeras
contain
primer
pcr
thermal
cycl
program
first
predenatur
min
follow
cycl
final
extens
min
aliquot
pcr
product
visual
ethidium
bromid
stain
separ
electrophoresi
agaros
gel
tri
borat
ethylenediamin
tetraacet
acid
buffer
ph
hr
imag
captur
densiti
assess
describ
supernat
sirnatr
cell
assay
presenc
cytokin
use
human
cytokin
antibodi
array
c
seri
accord
manufactur
instruct
raybiotech
norcross
ga
briefli
membran
block
cell
supernat
ad
incub
overnight
membran
wash
incub
biotinconjug
primari
antibodi
overnight
follow
three
wash
membran
incub
dilut
hrpconjug
streptavidin
hour
wash
detect
buffer
ad
imag
obtain
flour
max
multiimag
densiti
cytokin
protein
spot
quantifi
quantiti
one
analysi
softwar
version
clone
eosinophil
atcc
purchas
american
type
cultur
collect
final
differenti
cultur
carri
rpmi
cellgro
mediatech
inc
herndon
va
supplement
fetal
calf
serum
ngml
atlanta
biolog
atlanta
ga
penicillin
uml
streptomycin
humidifi
atmospher
carbon
dioxid
previous
describ
viabil
cell
harvest
experi
assess
trypan
blue
exclus
popul
cell
viabil
use
gener
superoxid
experi
cell
centrifug
g
min
wash
two
time
hank
balanc
salt
solut
hbss
superoxid
anion
gener
assess
microtit
plate
cellswel
total
volum
ml
hbss
contain
bovin
serum
albumin
ferricytochrom
c
without
superoxid
dismutas
treat
cell
cultur
supernat
microtit
plate
incub
atmospher
co
two
hour
absorb
read
nm
determin
superoxid
dismutaseinhibit
reduct
ferricytochrom
c
experi
conduct
duplic
triplic
indic
figur
legend
repeat
least
three
four
separ
occas
unless
otherwis
state
data
express
mean
sem
mean
triplic
one
experi
serv
one
observ
indic
oneway
analysi
varianc
anova
follow
either
tukey
multipl
comparison
dunnett
posttest
appropri
appli
experiment
result
determin
statist
signific
p
indic
group
silenc
alveolar
type
ii
epitheli
cell
receptor
accomplish
treat
cell
four
ontargetplu
sirna
duplex
individu
togeth
smartpool
nontarget
sirna
control
pool
four
sirna
confirm
minim
target
known
gene
human
cell
includ
experi
distinguish
sequencespecif
silenc
nonspecif
effect
result
flow
cytometri
studi
depict
figur
compar
nontarget
sirna
treat
cell
evid
treatment
duplex
duplex
smartpool
combin
greatli
reduc
cell
surfac
express
reduct
mrna
result
sirna
treatment
demonstr
pcr
use
rna
purifi
treat
cell
result
depict
figur
show
typic
imag
densitometr
analys
sever
gel
respect
result
indic
treatment
significantli
suppress
mrna
stimul
cell
immunoblot
experi
carri
demonstr
sirna
treatment
alter
total
protein
express
dot
blot
analys
total
cell
lysat
shown
figur
result
indic
constitut
presenc
untreat
cell
upregul
receptor
follow
stimul
suppress
protein
express
smartpool
individu
duplex
evid
dot
blot
imag
pixel
densiti
analys
three
experi
shown
figur
protein
express
compar
express
cell
treat
nontarget
sirna
follow
stimul
duplex
treatment
effect
protein
express
compar
nontarget
sirna
control
contrast
treatment
remain
sirna
duplex
result
follow
effect
protein
express
duplex
duplex
duplex
inhibit
cell
treat
combin
sirna
smartpool
express
decreas
shown
figur
western
blot
analys
corrobor
report
dot
blot
studi
result
sever
experi
analyz
densitometri
outcom
depict
figur
compar
nontarget
sirna
treat
cell
densitometri
data
confirm
duplex
combin
smartpool
induc
mrna
degrad
result
decreas
protein
express
respect
collect
data
demonstr
sirnainduc
posttranscript
silenc
valid
specif
posttranscript
silenc
parallel
studi
carri
two
asodn
sequenc
scrambl
control
result
antisens
concentr
nm
indic
concentr
depend
reduct
cell
surfac
receptor
select
concentr
depict
figur
cellquest
histogram
statist
analys
indic
follow
reduct
fluoresc
intens
antisens
treat
cell
versu
stimul
cell
absenc
antisens
nm
shown
nm
nm
alter
surfac
receptor
cell
treat
nm
sens
odn
data
shown
western
immunoblot
experi
carri
cell
lysat
prepar
alveolar
type
ii
cell
treat
asodn
sens
odn
control
result
shown
figur
demonstr
concentr
depend
decreas
cell
treat
nm
asodn
sequenc
stimul
cell
sens
sequenc
effect
collect
result
demonstr
sirna
asodn
effect
suppress
gene
express
previous
report
antagonist
decreas
stimul
releas
airway
epitheli
cell
interest
explor
effect
antisens
treatment
express
result
shown
figur
treatment
cell
antisens
significantli
decreas
amount
measur
whole
cell
lysat
contrast
antisens
significantli
decreas
stimul
releas
treatment
sens
asodn
sequenc
signific
effect
result
suggest
regul
may
partli
control
blockad
pathway
target
antisens
treatment
sinc
sirna
consid
novel
tool
inhibit
gene
function
human
diseas
interest
explor
possibl
sirna
deliv
airway
epitheli
cell
would
decreas
releas
ligand
specif
result
constitut
releas
releas
depict
figur
respect
expect
littl
constitut
releas
note
cell
stimul
absenc
transfect
mix
releas
pgml
data
shown
cell
treat
nontarget
sirna
transfect
mix
releas
pgml
treatment
cell
duplex
reduc
contrast
signific
inhibit
releas
note
duplex
combin
smartpool
percent
inhibit
releas
respect
alveolar
type
ii
cell
constitut
releas
increas
follow
treatment
cell
result
present
experi
indic
cell
constitut
releas
pgml
effect
constitut
releas
cell
treat
sequenc
shown
figur
signific
inhibit
releas
note
follow
treatment
transfect
mix
inhibit
follow
duplex
duplex
duplex
smartpool
interestingli
sirna
treat
cell
stimul
less
inhibit
measur
shown
figur
although
percent
inhibit
stimul
releas
duplex
treat
cell
smartpool
treat
cell
significantli
differ
nontarget
sirna
treat
cell
taken
togeth
result
suggest
treatment
alveolar
type
ii
epitheli
cell
sirna
significantli
influenc
releas
eotaxin
basal
stimul
condit
recent
report
human
membran
array
studi
reveal
unstimul
alveolar
type
ii
cell
releas
number
cytokin
thu
interest
explor
effect
sirna
treatment
cytokineschemokin
capabl
bind
cell
treat
either
nontarget
sirna
smartpool
sirna
without
subsequ
stimul
result
select
cytokin
capabl
bind
depict
figur
result
corrobor
sirna
effect
demonstr
previou
figur
thu
valid
cytokin
array
result
four
addit
chemokin
capabl
bind
significantli
increas
treatment
includ
rant
itac
comparison
nt
versu
sp
treatment
indic
signific
decreas
ligand
interest
includ
antagonist
mig
itac
mig
alter
sirna
treatment
contrast
data
indic
may
upregul
result
suggest
posttranscript
silenc
modul
chemokin
capabl
signal
receptor
either
agonist
antagonist
asthma
inflammatori
process
gener
toxic
level
reactiv
oxygen
speci
ro
includ
superoxid
activ
eo
alveolar
macrophag
neutrophil
stimul
cell
releas
activ
eo
compound
inflamm
therefor
eo
expos
medium
stimul
asodn
treat
airway
epitheli
cell
gener
eo
assess
depict
tabl
figur
respect
signific
decresas
gener
measur
eo
expos
supernat
collect
cell
pretreat
antisens
result
supernat
sirna
treat
cell
depict
figur
eo
gener
nmol
cell
incub
medium
exogen
ngml
respect
nontarget
sirna
treat
cell
supernat
result
differ
cell
treat
alon
duplex
treatment
cell
yield
supernat
decreas
gener
eo
data
suggest
product
releas
stimul
cell
contain
proinflammatori
mediat
includ
cc
chemokin
act
stimul
gener
eo
target
asodn
sirna
treatment
may
lead
desir
decreas
eo
activ
chemokin
ligandreceptor
pathway
orchestr
critic
event
underli
inflammatori
condit
airway
diseas
thu
chemokin
ligand
receptor
import
candid
develop
novel
antiinflammatori
strategi
present
studi
focus
airway
epitheli
cell
axi
viabl
target
develop
novel
posttranscriptionbas
therapi
interrupt
underli
proinflammatori
cycl
chronic
airway
diseas
express
eo
basophil
airway
epitheli
cell
subpopul
mast
cell
activ
cell
macrophag
dendrit
cell
present
experi
design
test
hypothesi
transfect
alveolar
type
ii
cell
asodn
sirna
result
downregul
surfac
decreas
synthesi
releas
modul
ligand
result
demonstr
asodn
sirna
decreas
mrna
turn
caus
decreas
protein
significantli
decreas
constitut
releas
likewis
significantli
reduc
downregul
chemokin
extend
noneotaxin
ligand
eo
bioactiv
reduc
respons
product
releas
sirna
treat
alveolar
type
ii
cell
intens
interest
develop
posttranscript
modul
gene
express
therapeut
approach
treatment
pulmonari
infect
lung
cancer
chronic
airway
diseas
cell
cultur
system
includ
alveolar
type
ii
epitheli
cell
system
valuabl
tool
delin
potenti
target
present
investig
cell
cultur
system
employ
demonstr
sirna
result
specif
reduct
target
gene
mrna
subsequ
protein
use
sever
effect
sirna
duplex
suggest
specif
effect
absenc
offtarget
effect
also
support
lack
effect
nontarget
duplex
design
scrambl
sequenc
present
human
genom
first
report
efficaci
sirna
downregul
well
known
ligand
name
collect
data
suggest
posttranscript
regul
chemokin
receptor
may
potenti
therapeut
approach
interrupt
proinflammatori
signal
human
possess
three
eotaxin
transduc
signal
predominantli
though
exclus
via
receptor
result
previou
investig
laboratori
demonstr
alveolar
type
ii
cell
constitut
express
cytokin
increas
express
synthesi
releas
larg
sustain
amount
elev
level
report
asthmat
lung
act
chemotact
agent
activ
effector
pathway
resid
cell
emigr
eo
leukocyt
importantli
present
investig
demonstr
posttranscript
silenc
decreas
releas
receptor
predomin
ligand
sinc
sever
resid
pulmonari
cell
express
produc
eotaxin
result
suggest
sirna
may
downregul
cognat
receptor
resid
cell
lung
subsequ
downregul
leukocyteattract
chemokin
favor
interrupt
persist
underli
inflamm
chemokin
modul
immun
system
respons
coordin
leukocyt
recruit
activ
innat
adapt
inflammatori
respons
complex
chemokin
network
add
challeng
design
inflammationtarget
therapi
cc
cxc
chemokin
network
categor
receptor
princip
agonist
antagonist
function
activ
implic
human
allergyinflamm
addit
three
eotaxin
known
agonist
includ
rant
mec
convers
high
affin
ligand
mig
itac
known
antagonist
case
asthma
increas
releas
sever
cc
chemokin
name
three
eotaxin
firmli
establish
herein
cytokin
array
result
demonstr
addit
eotaxin
sever
agonist
increas
stimul
untreat
alveolar
type
ii
cell
includ
stimul
cell
pretreat
sirna
signific
decreas
agonist
well
interestingli
mcp
rant
specif
chemotact
monocyt
lymphocyt
also
affect
antagonist
chemotact
lymphocyt
mast
cell
significantli
alter
sirna
treatment
collect
result
suggest
genespecif
silenc
may
extend
beyond
recruit
eo
may
also
includ
mononuclear
cell
promin
airway
mucosa
infiltr
activ
eo
consid
central
patholog
featur
chronic
airway
diseas
asthma
airway
epitheli
cell
import
sourc
cytokineschemokin
stimul
eo
bioactiv
includ
gener
reactiv
oxygen
speci
releas
leukotrien
degranul
eosspecif
cation
protein
releas
cytokin
compel
evid
indic
function
promot
eo
emigr
activ
support
prolong
recruit
activ
may
requir
expans
includ
addit
ligand
particular
thu
explor
effect
treatment
alveolar
type
ii
cell
bioactiv
eo
interest
sinc
eo
known
gener
gener
stimul
occup
receptor
significantli
reduc
level
gener
eo
expos
sirna
asodn
stimul
cell
supernat
result
impli
deplet
result
modul
ligand
would
result
effect
reduct
activ
eo
airway
summari
although
symptom
airway
diseas
may
control
need
therapi
provid
control
chemokinedriven
chronic
airway
inflamm
investig
focus
network
demonstr
alveolar
type
ii
cell
releas
may
downregul
posttranscript
silenc
concomit
decreas
addit
ligand
also
occur
togeth
reduc
eo
bioactiv
respons
product
releas
treat
cell
find
establish
appropri
target
develop
sirna
asodn
posttranscript
gene
inhibit
therapi
control
alveolar
inflamm
airway
diseas
firststrand
cdna
synthes
total
rna
revers
transcript
rt
cdna
amplifi
pcr
use
human
gapdh
primer
pcr
product
separ
electrophoresi
agaros
gel
stain
ethidium
bromid
mrna
express
captur
fluor
max
multiimag
panel
c
data
experi
express
rel
ratio
mean
sd
treatment
differ
significantli
p
nontarget
sirna
follow
treatment
group
indic
asterisk
cell
cultur
treat
sirna
stimul
ngml
describ
figur
panel
depict
typic
dot
blot
lysat
protein
probe
human
panel
b
summar
dot
blot
densiti
three
separ
experi
acquir
quantiti
one
analysi
softwar
data
express
mean
pixel
densiti
sem
panel
c
show
similar
experi
cell
lysat
protein
separ
electrophoresi
sdspolyacrylamid
gel
lysat
proteinlan
transfer
immobilonp
pvdf
membran
probe
human
gapdh
panel
depict
western
blot
band
densiti
ratio
three
separ
experi
express
rel
mean
ratio
sem
panel
b
asterisk
indic
treatment
differ
significantli
p
cell
treat
nontarget
sirna
follow
stimul
cell
treat
antisensesens
describ
figur
follow
without
panel
stimul
ngml
hr
panel
b
cell
lysat
prepar
total
protein
assess
protein
use
sandwich
elisa
asterisk
indic
treatment
differ
significantli
p
cell
stimul
absenc
oligonucleotid
cell
treat
hr
nm
sirna
nontarget
control
alon
smartpool
combin
presenc
dharmafect
treat
cell
monolay
wash
serumfre
medium
incub
addit
hr
absenc
panel
presenc
ngml
panel
b
quantifi
cultur
supernat
specif
sandwich
elisa
data
mean
sem
three
experi
perform
duplic
asterisk
indic
treatment
differ
significantli
nontarget
sirna
control
assess
dunnett
post
test
p
cell
treat
describ
figur
assess
cell
cultur
supernat
specif
elisa
follow
incub
without
panel
ngml
panel
b
data
mean
sem
three
experi
perform
duplic
asterisk
indic
treatment
differ
significantli
nontarget
sirna
control
assess
dunnett
post
test
p
cell
treat
nontarget
smartpool
sirna
follow
ngml
supernat
assay
presenc
cytokin
use
human
cytokin
antibodi
array
c
seri
imag
obtain
flour
max
multiimag
densiti
cytokin
protein
spot
quantifi
quantiti
one
analysi
softwar
version
data
normal
membran
posit
control
express
rel
pixel
densiti
mean
sd
two
sampl
anova
tukey
post
test
use
p
determin
signific
differ
nontarget
nt
nt
nt
sp
figur
superoxid
anion
gener
suppress
clone
eosinophil
cell
expos
supernat
treat
alveolar
type
ii
cell
alveolar
type
ii
cell
treat
describ
figur
supernat
use
stimul
eo
describ
tabl
addit
control
includ
eo
medium
control
medium
ngml
recombin
ad
signific
differ
nontarget
nt
sirna
supernat
asterisk
indic
treatment
differ
significantli
nontarget
sirna
control
assess
dunnett
post
test
p
